Article
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Liver international : official journal of the International Association for the Study of the Liver - 1 Jul 2014
Gardner Stephen, Cutrell Amy, Elko-Simms Cindy, Adkison Kimberly, Hamatake Robert, Walker Jill, Rodriguez-Torres Maribel, Hong Zhi
Abstract excerpt
BACKGROUND & AIMS: GSK2336805 is a HCV NS5A inhibitor for chronic hepatitis C (CHC). In a prior Phase I study, GSK2336805 was well tolerated and had an antiviral and pharmacokinetic profile suitable for once-daily administration. This 28-day, double-blind, randomized, placebo-controlled study evaluated once daily GSK2336805 60 mg alone or in combination with peginterferon alfa-2a (180 μg per week) and ribavirin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.